Importantly, TRIM3 overexpression correlated with poor survival of patients with ER+ breast cancer with tamoxifen resistance, identifying TRIM3 as a potential biomarker for the treatment of ER+ breast cancer. The gene discussed is TRIM3; the disease is breast carcinoma.